News >

Hurvitz Evaluates De-Escalation Strategies in Early-Stage HER2+ Breast Cancer

Caroline Seymour
Published: Wednesday, Sep 19, 2018

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD
Several studies have evaluated and confirmed the benefit of de-escalating therapy for patients with early-stage HER2-positive breast cancer, but whether these therapies should replace more traditional cytotoxic regimens has yet to be determined, explained Sara A. Hurvitz, MD.

, Hurvitz discussed these de-escalation strategies in early-stage HER2-positive breast cancer and novel HER2-targeted therapies in development.

OncLive: Can you elaborate on de-escalation strategies that are being explored in early-stage HER2-positive breast cancer?

Hurvitz: Our approach to early-stage HER2-positive breast cancer has changed in recent years. When trastuzumab was first FDA approved for the treatment of patients with HER2-positive early-stage disease, it was primarily for patients with tumors >2 cm or those with lymph node-positive disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication